Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer finally begins Phase III for GlycoMimetics sickle cell drug

This article was originally published in Scrip

Executive Summary

GlycoMimetics will receive the final $20m of a $35m milestone payment from Pfizer now that the big pharma company has initiated a long-delayed Phase III clinical trial for rivipansel (GMI-1070) in the treatment of patients hospitalized for painful vaso-occlusive crises associated with sickle cell disease.

You may also be interested in...



Sickle Cell Data Show Value Of Novartis’s Recently Acquired SEG101

Phase II SUSTAIN data presented at ASH show a statistically significant reduction in sickle cell pain crises for SEG101 (crizanlizumab), a potential blockbuster for Novartis, which recently said it will pay up to $665m for the antibody’s developer.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Related Companies

UsernamePublicRestriction

Register

SC029069

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel